Corneal perforation in ocular graft-versus-host disease

Cathy Y. Zhang a, Asim V. Farooq b, George J. Harocopos b,c, Eric L. Sollenberger a, Joshua H. Hou d, Charles S. Bouchard e, Christine Shieh f, Uyen L. Tran f, Anthony J. Lubniewski a, Andrew J.W. Huang a, Grace L. Paley a,∗

a Department of Ophthalmology & Visual Sciences, Washington University School of Medicine, 660 S Euclid Ave, St. Louis, MO, 63110, United States
b Department of Ophthalmology & Visual Science, University of Chicago, 5801 S Ellis Ave, Chicago, IL, 60637, United States
c Department of Pathology & Immunology, Washington University School of Medicine, 660 S Euclid Ave, St. Louis, MO, 63110, United States
d Department of Ophthalmology & Visual Neurosciences, University of Minnesota, 100 Church St SE, Minneapolis, MN, 55455, United States
e Department of Ophthalmology, Loyola University Health System, 2160 S 1st Ave, Maywood, IL, 60153, United States
f Department of Ophthalmology & Visual Sciences, Vanderbilt Eye Institute, 2311 Pierce Ave, Nashville, TN, 37232, United States

ARTICLE INFO

Keywords:
Graft-versus-host disease
Corneal perforation
Corneal ulcer

ABSTRACT

Purpose: Corneal perforation is a rare, vision-threatening complication of ocular graft-versus-host disease (GVHD) and is not well understood. Our objective was to examine the clinical disease course and histopathologic correlation in patients who progressed to this outcome.

Methods: This study is a retrospective case series from four academic centers in the United States. All patients received a hematopoietic stem cell transplant (HSCT) prior to developing ocular GVHD. Variables of interest included patient demographics, time interval between HSCT and ocular events, visual acuity throughout clinical course, corticosteroid and infection prophylaxis regimens at time of corneal perforation, medical/surgical interventions, and histopathology.

Results: Fourteen eyes from 14 patients were analyzed. Most patients were male (86%) and Caucasian (86%), and average age at time of hematopoietic stem cell transplant was 47 years. The mean interval between hematopoietic stem cell transplant and diagnosis of ocular graft-versus-host disease was 9.5 months, and between hematopoietic stem cell transplant and corneal perforation was 37 months. Initial best-corrected visual acuity was 20/40 or better in 9 eyes, and all eyes had moderate or poor visual outcomes despite aggressive management, including corneal gluing in all patients followed by keratoplasty in 8 patients. The mean follow-up after perforation was 34 months (range 2–140 months). Oral prednisone was used prior to perforation in 11 patients (79%). On histopathology, representative specimens in the acute phase demonstrated ulcerative keratitis with perforation but minimal inflammatory cells and no microorganisms, consistent with sterile corneal melt” in the setting of immunosuppression; and in the healed phase, filling in of the perforation site with fibrous scar.

Conclusions: In these patients, an extended time interval was identified between the diagnosis of ocular graft-versus-host disease and corneal perforation. This represents a critical window to potentially prevent this devastating outcome. Further study is required to identify those patients at greatest risk as well as to optimize prevention strategies.

1. Introduction

In recent years, the number of allogeneic hematopoietic stem cell transplants (HSCT) has steadily increased. HSCT has become the standard of care for many hematologic cancers as well as certain metabolic diseases and solid malignancies.1 Unfortunately, graft-versus-host disease (GVHD), which occurs when donor-derived T cells recognize host antigens as foreign and attack host tissue, continues to affect more than half of HSCT recipients.2

Ocular GVHD occurs in 40–60% of patients receiving allogeneic HSCT.1,3 It commonly manifests within 3 years post-HSCT,1 often with symptoms such as ocular irritation, foreign body sensation, burning,
pain, and blurry vision.\textsuperscript{1,4} Diagnostic criteria for ocular GVHD include new onset keratoconjunctivitis sicca and/or punctate keratopathy in the setting of post-HSCT.\textsuperscript{5} Aside from increasing systemic immunosuppression, treatment is primarily supportive and includes aggressive ocular lubrication, decreasing corneal inflammation, and providing support for the corneal and conjunctival epithelial surfaces.\textsuperscript{6} Artificial tears, topical and systemic cyclosporine, and topical steroids are commonly used, along with bandage soft contact lenses, therapeutic scleral contact lenses, antibiotics, and autologous serum tears.\textsuperscript{2,6}

Despite treatment, ocular GVHD may progress to sight-threatening complications including corneal ulceration and corneal perforation. The pathophysiology of non-infectious corneal ulceration and perforation as the result of ocular GVHD is not entirely clear, though it has been proposed that local inflammation and overexpression of inflammatory mediators similar to the mechanism behind autoimmune diseases such as rheumatoid arthritis and Sjögren's may play a major role.\textsuperscript{1,4} Past studies have asserted that use of topical or systemic corticosteroids as well as use of topical nonsteroidal anti-inflammatory drugs (NSAIDs) may correlate with corneal ulceration and perforation in patients with chronic GVHD.\textsuperscript{4,7} Local immunosuppression may also increase the risk of infectious corneal ulceration. In addition, while factors such as total body irradiation and immunosuppressive therapy have been linked to dry eye symptoms in patients post-HSCT,\textsuperscript{4} it is not known if these factors also contribute to the likelihood and rapidity of corneal perforation.

If the clinical course for corneal perforation were better described, then patients presenting with ocular GVHD could be assessed for their likelihood to progress to perforation and ideally managed to prevent this devastating event. Identifying patients at risk for ocular GVHD could be advantageous, as it has been noted that early treatment of ocular GVHD tends to be more effective, with patients less likely to progress to more serious disease manifestations.\textsuperscript{8} The purpose of our study was to examine the presentation and outcomes of patients with corneal perforation in the setting of ocular GVHD. We examined the clinical features, associated histopathology, and duration, timing, and types of pharmacologic agents used in these patients.

2. Materials and methods

\textbf{Study Design:} Institutional review board approval was obtained to conduct a retrospective chart review on patients who developed corneal perforation as a complication of ocular GVHD following HSCT. Patients were identified via an electronic medical record search for ICD-10 codes D89.81 (graft-versus-host disease) or T86.01 (bone marrow transplant rejection), and CPT codes for penetrating or lamellar keratoplasty, corneal gluing, or corneal surface reconstruction with amniotic membrane transplantation (65710, 65730, 65750, 65755, 65780, 65286), yielding 7 patients who presented to Washington University in St. Louis between January 1, 1960 to April 1, 2019. Additional patients were similarly identified and their charts reviewed at the University of Minnesota (3 patients), Loyola University (2 patients), and Vanderbilt University (2 patients).

\textbf{Patient Characteristics of Interest:} We gathered data on patient sex, race, age at HSCT, indication for HSCT, use of systemic corticosteroids and infection prophylaxis regimens at time of corneal perforation, and incidence of lamellar or penetrating keratoplasty in the affected eye. We also calculated the time intervals in months from HSCT to ocular GVHD diagnosis, HSCT to first corneal perforation, and ocular GVHD diagnosis to first perforation, when such records were available. We used the first HSCT date for patients who underwent more than one HSCT. Outliers were determined by calculating interquartile range (IQR) and excluding values that fell outside the bounds set by Q3 - 1.5*IQR.

In addition, we extracted best-corrected visual acuity (BCVA) in the affected eye at initial presentation to ophthalmology, at time of corneal perforation, and at the most recent follow-up visit. For patients who underwent penetrating keratoplasty or evisceration, histopathological results were reviewed. Histologic sections of the corneal buttons were processed for staining with hematoxylin and eosin (H&E) and for immunohistochemistry and were reviewed by an ocular pathologist (G. J.H.).

3. Results

In total, 14 eyes of 14 patients who had developed corneal perforation in the setting of ocular GVHD following HSCT, and who were treated at these academic ophthalmology departments, were identified. Patient demographics and the indication for HSCT in this cohort are summarized in Table 1. The mean age at the time of HSCT was 47 ± 13 years (standard deviation), and the majority of patients were male (12 patients, 86%) and Caucasian (12 patients, 86%). While this cohort had a variety of underlying hematologic malignancies, notably 7 patients (50%) had acute myeloid leukemia as an indication for HSCT.

Table 2 summarizes the time course of each patient, reporting the intervals between HSCT and initial ocular GVHD diagnosis, between HSCT and first corneal perforation, and between ocular GVHD diagnosis and first perforation. A number of cases had incomplete data pertinent to these categories, but in general the patients had long time intervals between ocular GVHD diagnosis and first perforation, with a mean interval of 24 months (range 5–47 months, with outlier exclusion). The mean interval between HSCT and the diagnosis of ocular GVHD was 9.5 months (excluding an outlier whose interval was 155 months), and the mean interval between HSCT and first corneal perforation was 37 months. Common presenting symptoms to ophthalmology included blurry vision, dry eye sensation, eye irritation, foreign body sensation, photophobia, and/or eye redness.

Table 3 shows the BCVA at various time points during the patients’ clinical courses, the length of follow-up for each patient after corneal perforation, the number of corneal transplants performed in the affected eye, and the size of the initial corneal transplant after perforation. Most of the patients presented to ophthalmology with good visual acuity; BCVA was 20/40 or better at initial presentation in 9 of 14 patients (64%) in the eye that later perforated, with 6 out of 14 patients (43%) having 20/20 vision initially. At time of corneal perforation, BCVA was consistently poor, with the best BCVA being 20/150 and 4 patients having hand motion or worse. The ulcerations appeared generally translucent, without associated infiltrate, consistent with sterile corneal “melt,” and none were culture positive for either bacteria or fungi.

Finally, despite the long periods of follow-up for most patients (mean 34
Systemic calcineurin inhibitors (cyclosporine, tacrolimus) or sirolimus patients (79%) and topical steroid eye drops were used by 8 patients 2 months prior to perforation. Notably, oral prednisone was used by 11 corneal perforation, various other treatments were employed, including of the patients with PKPs saw 20/90 or better compared to only 1 of the transplant. Although final visual acuity results were highly variable, half 20/100 or better in the affected eye, and 7 patients (50%) saw hand motion or worse at the last visit. Eight patients in our series had penetrating keratoplasties (PKPs) performed in the affected eye, with PKP sizes ranging from 2.0 to 9.0 mm. Only one of these initial corneal transplant procedures also utilized amniotic membrane at the time of the procedure, and none had tarsorrhaphy performed at the time of transplant. Although final visual acuity results were highly variable, half of the patients with PKPs saw 20/90 or better compared to only 1 of the 6 patients who did not undergo corneal transplant.

Table 2 summarizes the oral and topical immunosuppressive drug use, as well as the infection prophylaxis regimens, by each patient in the 2 months prior to perforation. Notably, oral prednisone was used by 11 patients (79%) and topical steroid eye drops were used by 8 patients (57%). The oral prednisone dosage ranged from 5 mg/day to 50 mg/day. Systemic calcineurin inhibitors (cyclosporine, tacrolimus) or sirolimus were used by nine patients (64%). Nine patients (64%) were also on topical antibiotic eyedrops during this time period. Prior to and after corneal perforation, various other treatments were employed, including punctal plugs or punctal cauteterization in 8 patients, bandage contact lenses or scleral lenses in 7 patients, tarsorrhaphy in 2 patients, topical cyclosporine or tacrolimus in 3 patients, and autologous serum tears in 2 patients.

Representative histopathology is shown for 2 patients who underwent corneal transplant or evisceration after corneal perforation (Fig. 1). Case 3 underwent evisceration due to expulsive hemorrhage and uveal prolapse resulting from acute corneal perforation. Histopathology (Fig. 1A) exhibited a wide perforation, partially filled with chronic inflammatory cells, granulation tissue, and heme, with iris tissue and pars plana prolapsing toward the perforation site. Adjacent to the perforation, there was calcific keratopathy and anterior stromal vascularization, but minimal acute and chronic inflammatory cells, consistent with corneal “melt” in the setting of chronic underlying immunosuppression. There was total endothelial cell loss. Gram and Gomori-methenamine-silver (GMS) stains were negative for microorganisms. Case 6 underwent multiple repeat penetrating keratoplasties for graft failure with healed perforations. Histopathology of a representative corneal button obtained from a re-graft procedure performed in the healed phase (Fig. 1B-E) demonstrated re-epithelialization over the antecedent perforation site, with an underlying wide gap in Descemet’s membrane centrally. Most notably, there was total endothelial cell loss associated with a fibrous retrocorneal membrane, which in the central region at the prior perforation site replaced the entire stromal thickness, corresponding clinically to a dense central scar. Anterior to mid-stromal vascularization was also appreciated peripherally to mid-peripherally. Clinically, the healed corneal perforations often exhibited stromal neovascularization and opaque scarring, as in this representative photographtaken approximately 5 months after corneal gluing for acute perforation in case 5 (Fig. 1F). Such corneal scars may be visually significant due to central location and/or induced astigmatism, and once the disease has quieted, may be conducive to visual rehabilitation via therapeutic scleral lenses or keratoplasty.

4. Discussion

While ocular involvement is not uncommon in patients with chronic GVHD, progression to corneal perforation is infrequent and described in only a handful of case reports. Combining case series of ocular GVHD in which corneal perforation was identified at two large tertiary referral centers, only 5 out of 307 patients suffered this devastating sequela (1.6%), suggesting that the incidence in the overall GVHD population is presumably even lower. Thus, studying this relatively rare complication can be challenging, and very little is currently known regarding

Table 2

| Case Number | HSCT to ocular GVHD diagnosis (months) | HSCT to first corneal perforation (months) | Ocular GVHD diagnosis to perforation (months) |
|-------------|----------------------------------------|------------------------------------------|-----------------------------------------------|
| 1           | 4                                      | 26                                       | 22                                            |
| 2           | 7                                      | 29                                       | 22                                            |
| 3           | 13                                     | 33                                       | 20                                            |
| 4           | 16                                     | 31                                       | 15                                            |
| 5           | 1                                      | 6                                        | 5                                             |
| 6           | 8                                      | 152                                      | 144                                           |
| 7           | unknown                                | 60                                       | unknown                                       |
| 8           | 155                                    | 202                                      | 47                                            |
| 9           | unknown                                | 98                                       | unknown                                       |
| 10          | unknown                                | 33                                       | unknown                                       |
| 11          | unknown                                | 20                                       | unknown                                       |
| 12          | 4                                      | 21                                       | 17                                            |
| 13          | 23                                     | 65                                       | 42                                            |
| 14          | unknown                                | 19                                       | unknown                                       |

Abbreviations: hematopoetic stem cell transplant (HSCT), graft-versus-host disease (GVHD).

*All durations were calculated from the first of the month. The date of ocular GVHD diagnosis was not available for a subset of records.

months, range 2–140 months), only 5 patients (36%) had a final BCVA of 20/100 or better in the affected eye, and 7 patients (50%) saw hand motion or worse at the last visit. Eight patients in our series had penetrating keratoplasties (PKPs) performed in the affected eye, with PKP sizes ranging from 2.0 to 9.0 mm. Only one of these initial corneal transplant procedures also utilized amniotic membrane at the time of the procedure, and none had tarsorrhaphy performed at the time of transplant. Although final visual acuity results were highly variable, half of the patients with PKPs saw 20/90 or better compared to only 1 of the 6 patients who did not undergo corneal transplant.

Table 4 summarizes the oral and topical immunosuppressive drug use, as well as the infection prophylaxis regimens, by each patient in the 2 months prior to perforation. Notably, oral prednisone was used by 11 patients (79%) and topical steroid eye drops were used by 8 patients (57%). The oral prednisone dosage ranged from 5 mg/day to 50 mg/day. Systemic calcineurin inhibitors (cyclosporine, tacrolimus) or sirolimus were used by nine patients (64%). Nine patients (64%) were also on topical antibiotic eyedrops during this time period. Prior to and after corneal perforation, various other treatments were employed, including punctal plugs or punctal cauteterization in 8 patients, bandage contact lenses or scleral lenses in 7 patients, tarsorrhaphy in 2 patients, topical cyclosporine or tacrolimus in 3 patients, and autologous serum tears in 2 patients.

4. Discussion

While ocular involvement is not uncommon in patients with chronic GVHD, progression to corneal perforation is infrequent and described in only a handful of case reports. Combining case series of ocular GVHD in which corneal perforation was identified at two large tertiary referral centers, only 5 out of 307 patients suffered this devastating sequela (1.6%), suggesting that the incidence in the overall GVHD population is presumably even lower. Thus, studying this relatively rare complication can be challenging, and very little is currently known regarding

Table 3

| Case Number | BCVA at first presentation to ophthalmology | BCVA at first corneal perforation | BCVA at last follow-up visit | Length of follow-up period after first perforation (months) | Number of corneal transplants in affected eye during follow-up interval | Size of corneal transplant graft (initial transplant after perforation) |
|-------------|--------------------------------------------|-----------------------------------|-----------------------------|-------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|
| 1           | 20/20                                      | Unknown                           | 20/60                       | 140                                                         | 2                                                            | Unknown size of PKP                                          |
| 2           | 20/60                                      | Unknown                           | Bare light perception       | 66                                                          | 0                                                            | N/A                                                        |
| 3           | 20/20                                      | 20/300                            | N/A                         | (evisceration)                                              | 48                                                          | 0                                                            | N/A                                                        |
| 4           | 20/20                                      | 20/70                             | Light perception 20/90      | 15                                                          | 0                                                            | N/A                                                        |
| 5           | 20/35                                      | Unknown                           | Count fingers at 4 feet     | 29                                                          | 1                                                            | 8.25 mm                                                     |
| 6           | 20/35                                      | Unknown                           | No light perception         | 31                                                          | 2                                                            | 8.25 mm                                                     |
| 7           | 20/300                                     | Unknown                           | 20/400                      | 31                                                          | 3                                                            | 8.25 mm                                                     |
| 8           | 20/300                                     | 20/150                            | Hand motion                 | 2                                                           | 0                                                            | N/A                                                        |
| 9           | 20/20                                      | Light perception                 | Hand motion                 | 20                                                          | 3                                                            | 9.50 mm                                                     |
| 10          | 20/40                                      | Unknown                           | 20/70                       | 41                                                          | 1                                                            | 4.00 mm                                                     |
| 11          | 20/25                                      | Unknown                           | 20/70                       | 4                                                           | 1                                                            | 2.00 mm                                                     |
| 12          | 20/20                                      | 20/400                            | 20/50                       | 3                                                           | 0                                                            | N/A                                                        |
| 13          | 20/50                                      | Hand motion                       | Light perception            | 45                                                          | 3                                                            | 9.00 mm                                                     |
| 14          | 20/200                                     | 20/200                            | 2                           | 0                                                            | N/A                                                        |

Abbreviations: Best-corrected visual acuity (BCVA), penetrating keratoplasty (PKP). All parameters refer to the eye with corneal perforation.
what factors may result in more severe disease and subsequent corneal perforation. Whereas many patients with ocular GVHD can maintain good visual acuity long-term, patients who suffer corneal perforation often have poor visual outcomes, demonstrating the importance of studying this condition. The majority of patients in our cohort were male and Caucasian. It is unknown whether the higher incidence of male patients was due to biological or social factors (e.g., delay in seeking medical care). However, the wider population of patients who undergo HSCT and are subsequently seen by ophthalmology departments included in our study are predominantly Caucasian. Out of the patients for whom the underlying indication for HSCT was able to be ascertained, 50% had AML. This is also likely representative of the overall ocular GVHD cohort, as 58% of all ocular GVHD patients at one of our institutions have AML as the indication for HSCT (unpublished data, Washington University in St. Louis).

On average, patients were diagnosed with ocular GVHD 9.5 months after HSCT and with corneal perforation 37 months after HSCT. Similarly, other studies have shown averages of between 24 and 26 months between HSCT and corneal perforation. The extended duration between HSCT and corneal perforation highlights the need for long-term follow-up. It also demonstrates the importance of early recognition and treatment of ocular GVHD-related complications, as the majority of our patients first presented with excellent vision in the eye that subsequently progressed to perforation. The presence of multisystem GVHD should also prompt referral to ophthalmology, as the majority of the patients in this cohort had additional non-eye organs affected by GVHD, consistent with other studies on ocular GVHD.

The majority of patients (71%) were on steroid regimens (including topical, systemic, or both) in the 2 months leading up to corneal perforation. The use of topical steroids has been associated with corneal ulceration and perforation in Sjögren’s syndrome. However, topical and systemic steroids are frequently used to treat chronic GVHD, and thus prolonged steroid use may be an indicator of more severe or recalcitrant inflammatory disease already at higher risk of corneal melt. Steroids, as well as other forms of immunosuppression, may also predispose to infectious keratitis. Although none of the cases in our cohort had a positive culture or histopathologic evidence of infection, this does not definitively rule out an infectious etiology in all cases. Nonetheless, the role of steroids in the long-term management of ocular GVHD should be carefully assessed.

It is likely that corneal melt in severe ocular GVHD has a multifactorial pathogenesis characterized by a chronic sicca microenvironment awash in a pro-inflammatory milieu. In prior clinicopathologic reports of corneal perforation in ocular GVHD, histopathology has confirmed stromal infiltration by chronic inflammatory cells. One report described stromal infiltration by CD68+ macrophages at the corneal perforation edge, but no CD8+ or CD4+ T cells, whereas another found stromal infiltration by CD8+ (but not CD4+) T cells. The former report also showed epithelial and stromal matrix metalloproteinase-9 (MMP-9), but not MMP-2, immunostaining at the perforation edge and also in the conjunctiva of GVHD patients. Epithelial cell and keratocyte apoptosis has also been demonstrated. Although these reports do not specifically comment on the degree of inflammation, their histologic photographs reveal a paucity of inflammatory cells, correlating with the clinically translucent appearance of the ulcerations, similar to the findings seen in our cases. Calcium deposition (a less common finding) and stromal vascularization have also been reported, as we likewise demonstrated on histopathology in several of our cases. Additionally, we showed that the healed phase of these perforations involved replacement of previously ulcerated corneal stroma by thick fibroconnective scar tissue. Similar to GVHD-associated corneal perforations, immunohistochemical analyses of paracentral sterile perforating corneal ulcers in patients with both rheumatoid arthritis and severe aqueous tear deficiency also displayed stromal infiltration by macrophages and T cells. The localization of these perforations in the central or paracentral cornea, similar to neurotrophic ulcers and persistent epithelial defects in limbal stem cell deficiency, may signal a common pathway of chronic inflammation that could reveal promising molecular therapeutic targets.

Unfortunately, current interventions after corneal perforation in the setting of GVHD do not appear to be very effective with regard to long-term visual acuity. At last follow-up (on average 34 months after first perforation), only a third of patients had a final BCVA of 20/100 or better in the affected eye, and approximately half were hand motion or worse. Although results were mixed, patients who underwent corneal transplantation tended to have a better chance at visual rehabilitation compared with non-surgical intervention (i.e. corneal gluing only), perhaps due to visually-significant residual corneal scarring.

The limitations of this study include its retrospective design, as well

### Table 4

| Case Number | Steroid-sparing immunosuppression | Oral steroid use | Topical steroid use | Infection prophylaxis |
|-------------|----------------------------------|-----------------|---------------------|-----------------------|
| 1           | None                             | Yes             | Unknown             | Valacyclovir, pentamidine, Doxycycline, vancomycin, trimethoprim-sulfmethoxazole, gatifloxacin, topical polymyxin B sulfate/trimethoprim, tobramycin, fluconazole, valacyclovir, Acyclovir, ofloxacin, dapsone, fluconazole, Ofloxacin, acyclovir, dapsone |
| 2           | Tacrolimus                        | Yes             | Yes                 | No                    |
| 3           | Tacrolimus                        | Yes             | Yes                 | Yes                   |
| 4           | Tacrolimus, mycophenolate moetil, ruxolitinib | Yes             | Yes                 | Yes                   |
| 5           | Tacrolimus                        | Yes             | Yes                 | Yes                   |
| 6           | Unknown                           | Unknown         | Unknown             | Unknown               |
| 7           | None                              | Yes             | Unknown             | Unknown               |
| 8           | None                              | No              | Yes                 | Valacyclovir, ofloxacin |
| 9           | Sirolimus                         | Yes             | Unknown             | Unknown               |
| 10          | Sirolimus                         | No              | Yes                 | Unknown               |
| 11          | Sirolimus, mycophenolate moetil   | Yes             | None                | Topical               |
| 12          | Tacrolimus                        | Yes             | Yes                 | Valacyclovir, fluconazole, levofloxacin, Valacyclovir, topical, Acyclovir, ofloxacin, dapsone, fluconazole, Ofloxacin, acyclovir, dapsone |
| 13          | Cyclosporine                      | Yes             | None                | True polymyxin B, topical, Acyclovir, trimethoprim-sulfmethoxazole, fluconazole, miconafungin, mexitoxacin |
| 14          | Sirolimus                         | Yes             | Yes                 | Acyclovir, trimethoprim-sulfmethoxazole, fluconazole, Valacyclovir, Ofloxacin, dapsone, fluconazole, Ofloxacin, acyclovir, dapsone |
as incomplete medical record documentation pre-dating electronic medical records in some cases. As such, we were unable to comprehensively report on all medications such as systemic immunosuppression that may have impacted the patients’ ocular outcomes. In addition, variation in documentation style by the different physicians prevented a standardized description of the eye exam for this retrospective study. While a relative strength is that the study included patients from four different institutions, all of these institutions are referral centers for tertiary ophthalmic care, so a selection bias may be present.

### 5. Conclusions

In summary, our study found that corneal perforation in the setting of ocular GVHD occurred an average of 3 years after HSCT, and that patients typically presented to the ophthalmologist prior to this event with good visual acuity. This demonstrates the importance of identifying at-risk patients and determining optimal prevention strategies, including regular ophthalmologic follow-up and patient education on signs and symptoms of ocular GVHD and its complications. We did not find evidence of infectious keratitis by culture or histopathology, which supports the hypothesis that these were predominantly sterile corneal ulcers that progressed to perforation. A role of steroids in pathogenesis remains unclear, but the use of steroids in the long-term management of ocular GVHD should be carefully considered. Our hope is that this study prompts further investigation of this rare but devastating entity.

**Patient consent**

Consent to publish the patient information in this brief report was not obtained. This report does not contain any personal information that could lead to the identification of the patients.

**Funding**

This work was supported in part by an unrestricted grant from Research To Prevent Blindness to the Department of Ophthalmology and Visual Sciences at Washington University. The funding organization had no role in the design or conduct of this research.
Intellectual property

We confirm that we have given due consideration to the protection of intellectual property associated with this work and that there are no impediments to publication, including the timing of publication, with respect to intellectual property. In so doing we confirm that we have followed the regulations of our institutions concerning intellectual property.

Research ethics

We further confirm that any aspect of the work covered in this manuscript that has involved human patients has been conducted with the ethical approval of all relevant bodies and that such approvals are acknowledged within the manuscript.

IRB approval was obtained (required for studies and series of 3 or more cases).

Authorship

All listed authors meet the ICMJE criteria. We attest that all authors contributed significantly to the creation of this manuscript, each having fulfilled criteria as established by the ICMJE.

We confirm that the manuscript has been read and approved by all named authors.

We confirm that the order of authors listed in the manuscript has been approved by all named authors.

Contact with the editorial office

The Corresponding Author declared on the title page of the manuscript is:
Grace L. Paley.
This author submitted this manuscript using his/her account in EVISE.

We understand that this Corresponding Author is the sole contact for the Editorial process (including EVISE and direct communications with the office). He/she is responsible for communicating with the other authors about progress, submissions of revisions and final approval of proofs.

We confirm that the email address shown below is accessible by the Corresponding Author, is the address to which Corresponding Author would like to receive all correspondence regarding this manuscript.

PALEY@WUSTL.EDU.

Declaration of competing interest

The following authors have no conflicts of interest to disclose: CZ, AF, GH, ES, JH, CB, CS, UT, AL, AH, GP.

Acknowledgments

None.

References

1. Berchicci L, Rabiolio A, Marchese A, et al. Ocular chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation in an Italian referral center. Ocul Surf. 2018;16(3):314–321. https://doi.org/10.1016/j.joxto.2018.04.001.
2. Anderson NG, Regillo C. Ocular manifestations of graft versus host disease. Curr Opin Ophthalmol. 2004;15(6):503–507. https://doi.org/10.1097/01. icl.0000145684.22362.46.
3. Westeneng AC, Hettinga Y, Lokhorst H, Verdonck L, van Dorp S, Rothova A. Ocular graft-versus-host disease after allogeneic stem cell transplantation. Cornea. 2010;29 (7):758–763.
4. Stevenson W, Shikari H, Saboo U, Amparo F, Dana R. Bilateral corneal ulceration in ocular graft-versus-host disease. Clin Ophthalmol. 2013;7:2153–2158.
5. Jagasia M, Greinix H, Arora M, et al. National institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant. 2015;21(3):389–401. https://doi.org/10.1016/j.bbmt.2014.12.001.
6. Shikari H, Antin J, Dana R. Ocular graft-versus-host disease: a review. Surv Ophthalmol. 2013;58(3):233–251. https://doi.org/10.1097/ ICL.0b013e3182a31050.
7. Inagaki E, Ogawa Y, Matsumoto Y, Kawakita T, Shimmura S, Tsuieba K. Four cases of corneal perforation in patients with chronic graft-versus-host disease. Mol Vis. 2011;17:598–606.
8. Balaram M, Rashid S, Dana R. Chronic ocular surface disease after allogeneic bone marrow transplantation. Ocul Surf. 2005;3(4):203–210. https://doi.org/10.1016/ S1542-0124(12)70079-0.
9. Lin X, Cavanagh HD. Ocular manifestations of graft-versus-host disease: 10 years’ experience. Clin Ophthalmol. 2015;9:1209–1213. https://doi.org/10.2147/OPTH. s84704.
10. Na K-S, Yoo Y-S, Mok J-W, Lee J-W, Joo C-K. Incidence and risk factors for ocular GVHD after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2015;50(11):1459–1464. https://doi.org/10.1038/bmt.2015.187.
11. Wang JCC, Teichman J, Mustafa M, O’Donnell H, Broady R, Yeung SN. Risk factors for the development of ocular graft-versus-host disease (GVHD) dry eye syndrome in patients with chronic GVHD. Br J Ophthalmol. 2015;99(11):1514–1518. https://doi.org/10.1136/bjophthalmol-2014-306438.
12. Pfister R, Murphy G. Corneal ulceration and perforation associated with Sjögren’s syndrome. Arch Ophthalmol. 1980;98(1):89–94. https://doi.org/10.1001/archophthalm.1980.01000000001006.
13. Mohammadpour M, Maleki S, Ilahemi H, Beheshtnejad AH. Recurrent corneal perforation due to chronic graft versus host disease: A clinicopathologic report. J Ophthalmic Vis Res. 2016;11(1):108–111. https://doi.org/10.4103/2008-322X.180705.
14. Yeh P, Hou Y, Lin W, Wang I, Hu F. Recurrent corneal perforation and acute calcareous corneal degeneration in chronic graft-versus-host disease. J Formos Med Assoc. 2006;105(4):334–339.
15. Suzuki M, Usui T, Kinoshita N, Yamagami SAS. A case of sterile corneal perforation after bone marrow transplantation. Eye. 2007;21(1):114–116. https://doi.org/10.1038/sj.eye.6702429.
16. Yoshida A, Kawano YI, Kato K, et al. Apoptosis in perforated cornea of a patient with graft-versus-host disease. Can J Ophthalmol. 2006;41(4):472–475. https://doi.org/10.1016/S0008-4182(06)00104-4.
17. Kerrvick G, Pflugfelder S, Haimovic R, Brown H, Tozman E, Yee R. Paracentral rheumatoid corneal ulceration. Clinical features and cyclosporine therapy. Ophthalmology. 1992;99(1):80–88.
18. Bonini S, Rama P, Olzã D, Lambiase A. Neurotrophic keratitis. Eye. 2003;17(8):989–995. https://doi.org/10.1038/sj.eye.6700616.
19. Saito T, Nishida K, Sugiyama H, et al. Abnormal keratocytes and stromal inflammation in chronic phase of severe ocular surface diseases with stem cell deficiency. Br J Ophthalmol. 2008;92(3):404–410. https://doi.org/10.1136/bjo.2007.127739.